ABL1 hyperactivation has been shown in other neurodegenerative diseases with inhibitor treatment generally reported as beneficial for Alzheimer’s disease (AD), Niemann-Pick Type C (NPC), and amyotrophic lateral sclerosis (ALS) (Derkinderen et al., 2005; Jing et al., 2009; Klein et al., 2011; Schlatterer et al., 2011; Imamura et al., 2017; Osaki et al., 2018; Riancho et al., 2018). Here, ABL1 is linked to neurodegenerative disease.